ChemoCentryx competitors

ChemoCentryx's competitors include Oxis International, Inovio Pharmaceuticals, Radius Health and Flexion Therapeutics
Add company...
ChemoCentryx
ChemoCentryx develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Oxis International
Oxis International, Inc. through its wholly owned subsidiary Oxis Biotech, Inc., is engaged in the developement of immunotherapies for cancer treatment.
Inovio Pharmaceuticals
Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid immunotherapies and vaccines.
Radius Health
Radius is a biopharmaceutical company developing new therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases.
Flexion Therapeutics
Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.
Founding Date
Founding Date
1997
Founding Date
1965
Founding Date
1979
Founding Date
2003
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Mountain View, US HQ
Locations
Tampa, US HQ
Locations
Blue Bell, US HQ
San Diego, US
San Diego, US
Locations
Waltham, US HQ
Locations
Burlington, US HQ
Employees
Employees
62
Employees
N/A
Employees
239
Employees
229
Employees
95
Valuation ($)
Valuation ($)
551.6 m
Valuation ($)
1.5 k
Valuation ($)
411.7 m
Valuation ($)
967.7 m
Valuation ($)
828.5 m
Facebook likes
Facebook likes
N/A
Facebook likes
222
Facebook likes
265
Facebook likes
N/A
Facebook likes
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
73
Twitter followers
7 k
Twitter followers
506
Twitter followers
527

Financial

Revenue (est.)
Revenue (est.)
$82.5m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$42.2m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Net income
Net income
$17.9m (FY, 2017)
Net income
$9.8m (FY, 2016)
Net income
($88.2m) (FY, 2017)
Net income
($254.2m) (FY, 2017)
Net income
($137.5m) (FY, 2017)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
2 (FY, 2016)
Patents Issued
620 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 1.4m
Total funding raised
$ 63.3m
Total funding raised
N/A
Total funding raised
$ 107m
For sources of this data, please see the company profileDownload Excel

View company profiles

Oxis International
HQ
Tampa, US

Oxis International, Inc. through its wholly owned subsidiary Oxis Biotech, Inc., is engaged in the developement of immunotherapies for cancer treatment.

View company
Inovio Pharmaceuticals
HQ
Blue Bell, US
Employees
239

Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid immunotherapies and vaccines.

View company
Radius Health
HQ
Waltham, US
Employees
229

Radius is a biopharmaceutical company developing new therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases.

View company
Flexion Therapeutics
HQ
Burlington, US
Employees
95

Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.

View company